Skip to content

Effect of Time-restricted Eating on Blood Glucose and Behavior in Patients With Type 2 Diabetes Mellitus

Effect of Time-restricted Eating on Blood Glucose and Behavior in Patients With Type 2 Diabetes Mellitus

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04841837
Acronym
TREAT BB
Enrollment
35
Registered
2021-04-12
Start date
2021-04-15
Completion date
2022-12-31
Last updated
2022-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Keywords

Time-restricted feeding, Type 2 diabetes mellitus

Brief summary

Diet management could improve blood and weight control in patients with diabetes mellitus. Time-restricted feeding is a novel dietary tool that limits time of energy intake without altering diet quality or quantity. This study aims to assess the effect of 10-hour time-restricted feeding on metabolism and behavior in patients with type 2 diabetes mellitus.

Interventions

limit daily food intake to a period of 10 hours

Sponsors

Peking University Third Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Diagnosed with type 2 diabetes mellitus 2. HbA1c 7.0% to 8.5% 3. BMI ≥ 24 kg/m2 4. Time of energy intake ≥ 12 hours per day, ≥ 4 days per week 5. Ability to use smart phone and app, to follow study protocol 6. Sign informed consent

Exclusion criteria

1. Use insulin, long-acting insulin secretagogues, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor 2. Suffer from disease influence eating: mental disease, subtotal gastrectomy, inflammatory bowel disease, uncontrolled thyroid disease 3. Work state affect eating time: constant night duty, constant long-haul international travel 4. Smoking 5. Drinking 6. Severe disease: severe cardiovascular and cerebrovascular disease, uncontrolled arrhythmia, heart failure, acute and chronic renal dysfunction, liver cirrhosis, malignancy, anemia 7. Suffered from infectious disease: pulmonary tuberculosis, AIDS 8. Dyskinesia 9. Body weight change ≥ 5 kg in the past 3 months 10. Hospitalized in the past 3 months 11. Used antibiotics for ≥ 3 days in the past 3 months 12. Diagnosed with type 1 diabetes mellitus 13. Pregnancy, lactating 14. Participating in other clinical trials in the past 1 months

Design outcomes

Primary

MeasureTime frame
HbA1cthrough study completion, an average of 12 weeks
Mean blood glucosethrough study completion, an average of 12 weeks
Time in rangethrough study completion, an average of 12 weeks

Secondary

MeasureTime frameDescription
Body weight (kg)through study completion, an average of 12 weeksElectronic weighing scale will be used to weigh participants
Compliance of time-restricted feedingthrough study completion, an average of 12 weeksPercent of days when the participants follow 10-hours window of calorie intake
Body composition (fat and muscle mass)through study completion, an average of 12 weeksBody composition analyzer will be used to analyze fat and muscle mass
Adverse eventthrough study completion, an average of 12 weeks
type and proportion of intestinal florathrough study completion, an average of 12 weeksCollect fecal specimens, analyze the types and proportion of intestinal flora

Countries

China

Contacts

Primary ContactHaining Wang
hainingmail@bjmu.edu.cn010-82266920
Backup ContactWei Fu
fuweiputh@bjmu.edu.cn010-82266920

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026